Molecular dynamics studies reveal structural and functional features of the SARS-CoV-2 spike protein

Ludovico Pipitò | Roxana-Maria Rujan | Christopher A. Reynolds | Giuseppe Deganutti

Centre for Sport, Exercise and Life Sciences (CSELS), Faculty of Health and Life Sciences, Coventry University, Coventry, UK

Correspondence
Giuseppe Deganutti, Centre for Sport, Exercise and Life Sciences (CSELS), Coventry University, Coventry CV1 2DS, UK.
Email: ad5288@coventry.ac.uk

Funding Information
Coventry University

INTRODUCTION

The year 2019 signaled the start of the worldwide outbreak of Coronavirus disease (Covid-19)\textsuperscript{[1–3]} from the\textit{Coronaviridae} SARS-CoV-2 virus, which counts around 360 million cases around the world with more than 5.6 million certified deaths (WHO dashboard, January 27, 2022).\textit{Coronaviridae} is an enveloped positive-stranded, non-segmented RNA virus with a genome of about 30 kb.\textsuperscript{[4]}\textit{Coronaviridae} viruses are responsible for cardiovascular, hepatic, respiratory, gastrointestinal, and neurological diseases, with major symptoms associated with a hyperbolic expression of proinflammatory signals and cytokines such as interleukins, interferon-gamma (IFN-\(\gamma\)), IFN-\(\gamma\) induced protein 10 (IP-10), macrophage inflammatory protein 1A and 1B (MIP-1A, MIP1-B), platelet-derived growth factor (PDGF), tumor necrosis factor (TNF-\(\alpha\)), and vascular endothelial growth factor (VEGF).\textsuperscript{[5]}

The SARS-CoV-2 infection mechanism depends on the transmembrane spike protein (S protein, Figure 1A,D)\textsuperscript{[6,7]} a highly conserved structure amongst the\textit{coronaviridae} family responsible for extracellular binding and cell membrane fusion.\textsuperscript{[8]} It characterizes the shape of this family of viruses, giving it the “solar” crown aspect\textsuperscript{[9]} they are named after. The SARS-CoV-2 strain shows a selective affinity for the angiotensin-converting enzyme 2 (ACE2, Figure 1A) receptor, a type 1 transmembrane protein with an external peptidase domain (PD) normally responsible for the conversion of angiotensin hormone into angiotensin II.\textsuperscript{[10]}

The S protein has aroused the interest of medical and pharmaceutical research to prevent infection and reduce the burden of clinical intervention. It is a homotrimer class I fusion protein, with each protomer composed of domain S1 and S2 (in the prefusion conformation, Figure 1A).\textsuperscript{[11]} The S1 structure is responsible for binding ACE2 (Figure 1A–C), before the conformational change in the...
FIGURE 1  The S protein is the first promoter of SARS-CoV-2 internalization. (A) Overall architecture of the complex between S protein (prefusion conformation, cyan) and ACE2 (violet); glycans on S protein are in van der Waals spheres; the relative positions of the plasma and viral membranes are reported. (B) Magnification of the S1 ectodomain (glycans removed for clarity); the RBD in the up conformation is responsible for binding ACE2. (C) Magnification of the interface between the RBD and one of the ACE2 monomers; the interactions can be divided according to the relative position into sites 1 to 3 (red circles). (D) Fully glycosylated S protein (https://charmm-gui.org/?doc=archive&lib=covid19) with the S1 and S2 units highlighted. The NTD, RBD, CTD, S1/S2 cleavage site, FP, HR1, HR2, TM, and CD are indicated. Glycans are shown in licorice. ACE2, angiotensin-converting enzyme 2; CD, cytosolic domain; CTD, C-terminal domain; FP, fusion peptide; HR, heptad repeat; NTD, N-terminal domain; RBD, receptor-binding domain; TM, transmembrane domain.
FIGURE 2  S protein deposited structures in the protein data bank. (A) SARS-CoV-2 protein structures released and ordered according to month and year of publication from the Protein Data Bank [18] (B) S protein structures only, ordered according to resolution unnatural rigidity that characterizes most X-ray crystallography and cryo-EM structures, allowing the investigation of possible cryptic binding pockets, allosteric effects, and structural changes in response to the binding.

In this review, we recapitulate the MD studies that have expanded our knowledge of the SARS-CoV-2 S protein flexibility and antibody (Ab) recognition and summarize their contribution to drug repurposing campaigns.

MOLECULAR DYNAMICS SIMULATIONS UNCOVER THE S PROTEIN FLEXIBILITY

Since the first cryo-EM structures of the S protein became available to the scientific community, it has been possible to investigate the conformational changes and the dynamic processes involving the S protein through MD simulations. One of the limits of the S protein structure experimentally determined is the scarcity of structural information about the post-translational glycosylation, due to the high dependency on the organism used for protein expression. To address this aspect, Woo et al. proposed a set of complete and fully glycosylated (Figure 1) S protein models [29], corroborating Wrapp et al.’s structure of the spike protein glycosylated in 44 out of 66 possible sites in the ectodomain region [11] including also Watanabe and coworkers glycans’ specifications [30].

A study by Turoňová et al. [18] as cited by Choi et al. [31] showed that the S1 domain displays structural compactness, while the stalk is characterized by two flexible portions, at the heptad-repeat 2 (HR2) linker and the heptad repeat transmembrane portion (HR2-TM), respectively. Such findings are in line with the experimental observation that the
S protein can tilt up to 90° toward the membrane, with an inclination of 48° (to the membrane normal) being most likely to occur. Such movements might favor ACE2 binding by scanning the surrounding space for a possible alignment with the receptor, while indirectly exposing cryptic epitopes. These findings, in context with the cryo-EM results, highlighted the importance of S2 flexibility, which plays a crucial role in conformational changes, alignment, and membrane fusion process. However, the limitations of the timescale in MD simulations restrict the exploration of long-lasting contacts between the protein and the receptor, thus limiting our ability to characterize the interaction network that contributes to the binding process.

The sequence of conformational changes on the S2 domain, necessary for membrane fusion, is triggered at the S1/S2 cleavage site on residues Pro681-Arg684 and facilitates the exposure of the FP. However, the experimental determination of these conformational changes is difficult due to the rapid timescale involved. A computational attempt was made by Remington et al. through the use of nontargeted parallel cascade selection MD (nt-PaCS-MD). The variational approach to Markov processes (VAMP) analysis indicated distinct conformational changes in cleaved SARS-CoV-2-spike models at the level of residues Val705–Asp1146 and residues Ser816–Asp1146. These changes seemed necessary to expose the fusion peptide (FP) and rearrange the region between residues Ile818–Val826 of the FP into an outward-facing helical structure that might mechanically initiate membrane fusion, indicating the crucial role of the S1/S2 cleavage site in facilitating the fusion mechanism. These findings suggest that drug discovery could target the S1/S2 cleavage site to hamper an efficient exposition of the FP, therefore interfering with the membrane fusion mechanism.

The differences between SARS-CoV and SARS-CoV-2 were addressed to understand the reasons behind SARS-CoV-2’s high infectivity and the molecular mechanisms required for effective therapy development. Furthermore, due to the presence of multiple mutations that differentiated SARS-CoV-2 and its variants from the original SARS-CoV, the molecular investigation of residues and conformational differences became necessary for a prompt pharmaceutical response. MD studies of SARS-CoV-2 have indicated accentuated flexibility compared to its predecessor SARS-CoV in segments of the RBD implicated in the molecular recognition of ACE2, more precisely in the region comprising residues Gln474–Gly485, Cys488–Phe490, and Ser494–Tyr505 of the RBD, which also enhances binding to the ACE2 receptor in B.1.351 and B.1.1.7 variants. It was possible, through MD simulations in combination with free energy perturbation (FEP), to assess the effect of mutations such as Asn501Tyr and Glu484Lys; the calculations indicated that the binding to ACE2 improved by 4.5 and 1.3 kcal/mol, respectively. The flexibility of RBD in the “up” conformation has been proposed as a determinant for the high propensity of SARS-CoV-2 to reach ACE2, giving rise to the high infectivity associated with SARS-CoV-2 compared to SARS-CoV. MD investigations allowed a broader analysis of the interaction network between ACE2 and RBD, which was not observed in the static cryo-EM or X-ray crystal structures. MD simulations showed a large interaction network between residues Ile21, Gln24, Thr27, Phe28, Asp30, Glu35, Asp38, Ala80, Met82, and Tyr83 of ACE2 and the RBD.

A study by Barros et al. indicated that ACE2 presents great motility when in contact with the S protein, suggesting that rotation of the catalytic zinc-binding PD along the transmembrane domain axis could sterically accommodate multiple ACE2 bindings. This large shift appeared to be enhanced by five glycans residues bound to Asn53, Asn90, Asn103, Asn322, and Asn546 of ACE2, with Asn53 involved in both intramolecular homodimer and heterodimer contacts. The results by Williams et al. in conjunction with those by Barros, indicated that in the RBD-ACE2 interaction pattern, residues Phe486, Asn487, and Tyr489 are responsible for the adaptive flexibility of the RBD in establishing strong interactions with ACE2. Taken together, these results describe the synergy between a strong ACE2-binding RBD, which once locked, is carried by the rotation of the ACE2 axis, allowing for multiple receptor engagement and a sequential binding mechanism. At the same time, this study demonstrated how mutations in that RBD sub-region are crucial in the selective pressure of the virus, altering the flexibility of RBD and interfering in intra-monomer interactions within the RBD. From a geometric perspective, effective interaction between the SARS-CoV-2-spike protein and ACE2 would occur at an angle of inclination between the apical portion of RBD “up” and ACE2 of at least 52°. Such MD results indicated that RBD “up” conformations have a large degree of maneuver to achieve sufficient residue exposure for ACE2 binding. Although MD is able to describe the dynamic events that lead to conformational changes and new interactions, predictions are still limited by the computational cost and represent a simplified scenario, where the complexity of a cellular microenvironment cannot be adequately represented.

**MOLECULAR DYNAMICS SIMULATIONS TO EXPLORE RARE S CONFORMATIONAL CHANGES**

The activation of a protein occurs through a series of conformational changes driven by molecular interactions with the intended target. The exploration of metastable states is necessary to understand the intermediate steps occurring during molecular events, and, therefore, identify possible therapeutic targets to interfere with the functional pathway.

However, large protein conformational rearrangements usually take place in the millisecond or second timescale, far beyond the time simulated in MD, which is usually within tens of microseconds. In such a context, the implication of this is that rare conformational changes can be missed. It is, therefore, necessary to apply enhanced or adaptive sampling algorithms to overcome this intrinsic limitation of the sampling to explore drastic structural changes in proteins.

From this perspective, weighted ensemble (WE) MD allows sampling of rare events drastically increasing the computational efficiency. With WE, multiple simulations are run in parallel and the trajectories that explored new values of a metric decided a priori (a distance between atoms in the simplest case) are retained and...
replicated, thus minimizing the randomness of conformational exploration. By using the WE path-sampling strategy, Sztaín et al.\cite{51} were able to simulate the transition state of RBD from “down” to “up,” uncovering the crucial role of several glycan residues in allosterically stabilizing the “up” state. While Asn165 and Asn264 shield the RBD acting as an “up” state stabilizer.\cite{46,47} Asn343 pushes the RBD to the final “up” state interacting with residues Phe490, Tyr489, Phe456, and Arg457 on the interaction portion of the ACE2 binding motif.\cite{45} More recently, it has been suggested that glycans attached to Asn165 and Asn343 contribute to the overall stability of the RBD open conformation.\cite{46}

An approach combining WE and artificial intelligence (AI) was adopted by Casalino et al.\cite{48} to evaluate transition conformational during the binding between fully glycosylated S protein and ACE2. This confirmed the role that the two N-glycan residues linked to Asn165 and Asn234 have in modulating the dynamics of the S protein’s RBD, contributing to the axial mobility of ACE2 while triggering the opening of RBD in a “hand jive” motion. Yao et al.\cite{49} analyzed the molecular architecture of SARS-CoV-2, from cryo-electron tomography (cryo-ET) and subtomogram averaging (STA) highlighting the complex composition of N-glycans, which is the result of unions between branched oligomannose and hybrids units. Such complex glycan ramifications also appears to be present on Asn234, whose allosteric role in the conformational change of RBD from “down” to “up” has been demonstrated by Casalino et al.\cite{48}

In a separate study, all-atom steered MD (SMD) forced the RBD from “down” to “up” and highlighted the conformational changes that occur during the breaking of the salt bridges between the RBD and the neighboring protomers, that is, the salt bridges that keep RBD in an inactive “down” state.\cite{50} These intramolecular salt bridges, Lys378-Glu988 and Lys386-Asp985 within the S2 domain, and Glu516-Lys202 within the NTD are mainly responsible for the inactive “down” state of the monomers and prevent the interactions with ACE2. Data obtained through targeted molecular dynamics (TMD) have shown how glycans on RBD residues Asn165, Asn234, and Asn343 can act as position lockers for the active “up” conformation,\cite{51} stabilizing a set of interdomain salt bridges involving Lys417, Arg408, and Lys378. Furthermore, glycans on Asn165 and Asn234 were proposed to shield the epitopes (Figure 3), while locking the RBD in the “up” state.\cite{47}

The description of the RBD transition from the down to the up states is a nontrivial task, essential for understanding the protein activation and providing valuable information about cryptic binding pockets. A recent study by Dokainish et al.\cite{52} described the opening of RBD by adopting the new generalized replica exchange method with solute tempering of selected surface charged residues (gREST, SSCR), an enhanced method derived from generalized replica exchange with solute tempering (gREST).\cite{53} In this study, a selection of charged residues at the RBD interface was regarded as the solute region for gREST, exploring a range of temperatures while the solvent was kept at a constant temperature. The results highlighted the important intra-chain interaction between R408 (chain A) and the proximal D406 (chain C) and the stabilizing role of the glycan on N165 for the “down” state, while the glycans on N343 and N234 supported the opening of the chain and the stabilization of the “up” state, respectively. The glycan on N343 interacts with Y489 and Q493 in the “up” state, contributing to structural stabilization, with the interdomain contribution of residues S477-T385, Q493-C379, Y489-T385, and Q493-K378 pairs.\cite{51}

A remarkable effort was made by Zimmerman et al.\cite{54} to explore large conformational changes through Markov-state models (MSMs) combined with the computational power provided by “citizen-scientists” from the “Folding@home” project (http://foldingathome.org), very long time scale simulations, in conjunction with the FAST algorithm, described the large conformational changes on the S protein which opened the RBD from its “down” to the “up” state, while the RBD domain twisted outward, exposing new cryptic epitopes.

**HIDE AND SEEK: THE HUNT FOR EPITOPES THROUGH MD**

Access to the S protein epitope(s) is necessary for antibody binding (Figure 3).\cite{55} From this standpoint, long MD simulations might unveil cryptic epitopes. Sikora et al.\cite{55} performed an extensive simulation of four S proteins embedded in a membrane for a total of 2.5 μs. The resulting trajectories were analyzed through simulated illumination analysis and rigid docking of the antibody CR3022. In the illumination analysis, randomly oriented rays emanated from a half-sphere at the center of mass of the S protein. Rays are then absorbed by the first heavy atom they meet within 1.5 Å. Single S protein structures are collected every 10 ns. To evaluate the shielding effect of glycans, the analysis was replicated without their presence. The results indicated that glycans reduce the S protein accessibility by up to 80%, with the most marked effect occurring in the stalk region close to the viral membrane. An interesting ab initio epitope mapping method was used by Serapian et al.\cite{56} Possible epitopes were classified according to the most marked effect occurring in the stalk region close to the viral membrane. The data agrees with the experimentally detected epitope recognized by antibodies CR3022, 4A8, S309, and EY6A.

The use of small molecules or cosolvents as probes in MD simulations (mixMD) increases the chance of discovering cryptic niches or epitopes on the surface of a protein. Through MixMD is possible to map interesting interaction sites by considering the frequency of contacts between protein and probe, resulting in a volumetric map. Using a concentration around 1%-5% cosolvent usually improves the sampling of hot spots for interactions without denaturing the protein. Pyrimidine (Py), acetonitrile, and isopropanol were used to discover possible docking niches on the interface between RBD and ACE2, and to inspire the drug design of antagonists or antibodies.\cite{57} Py showed the most relevant volumetric maps within the RBD that spans from residue Gln498 to residue Tyr505. Knowledge of these types of interactions, in conjunction with the molecular mechanics with generalized Born surface area solvation (MM-GBSA) analysis, leads drug design processes and virtual screening in concordance with
FIGURE 3  Human antibodies can bind to different S protein epitopes. The binding position of five human Abs on the surface of the S protein, is colored according to the legend. Abs names and protein data bank database IDs are reported in the legend. The S protein is represented as a white surface, with the RBD in red. Abs, antibodies; RBD, receptor-binding domain

experimental data from antibodies, with the data suggesting a set of new molecules (DB02651, DB03714, DB08248, and DB14826) as possible RBD interaction modulators.

COMPUTER-AIDED DRUG REPURPOSING TO TACKLE COVID19: THE ROLE OF MOLECULAR DYNAMICS SIMULATIONS

A huge drug repurposing effort (Box 1) was put in place, world-wide, to shorten as much as possible the approval of therapeutics against SARS-CoV-2 validated targets. Necessarily, the S protein has been one of the most investigated COVID-19 therapeutic targets due to its unique function and central role in the early stage of infection.

The general idea behind targeting the spike protein is to act as a preventive defense against infection, with the intent of minimizing the risk of triggering a potentially dangerous over-reaction of the immune system, reducing de facto the burden on the public health sector. In May 2020, news about the efficacy against COVID-19 of hydroxychloroquine (HCQ) originated in China, and the use of HCQ and azithromycin (ATM) was indicated as a possible front-line treatment. Simulations indicated that HCQ and ATM would have a synergistic effect in the treatment of the infection, where HCQ acts as a competitive binder against gangliosides, another proposed receptor for S protein, and ATM interacts with the tip of SARS-CoV-2 spike. Although these results seemed promising, the outcomes of clinical trials appeared highly controversial and the hypothesis of adopting the combined HCQ and ATM therapy has been abandoned.

To face the threat of SARS-CoV-2 and its mutations, including the British (alpha) variant large companies such as Pfizer BioNTech and AstraZeneca have developed vaccines capable of activating an immunogenic response against the S protein. A global vaccination campaign has started, with more vaccines currently under development all around the world.

However, as low-income countries struggle to have access to vaccines and immunosuppressed and allergic subjects cannot take advantage of the protection offered, alternative therapeutic approaches are still needed. Also, despite the high efficacy of vaccines, the full compliance of the population of high-income countries is yet to be reached, due to the limited knowledge of the long-term effects of new mRNA technologies and their implementation. In this scenario, drug repurposing could bring many advantages in terms of risk control and unwanted side effect management – because repurposed drugs have

Box 1

A possible strategy to overcome the barriers in the research and development of new active compounds is through drug repurposing of existing formulations for a different therapeutic indication (drug repurposing is usually characterized by a substantial variation from its original use). Since the COVID-19 outbreak, the alarming spread of the virus and the gravity of the infection led the scientific and medical community to seek rapid responses. The general approach to drug repurposing ideally starts with three steps: identifying the candidate molecule to generate the hypothesis, preclinical studies of the candidate molecule, and evaluation of efficacy in phase II clinical trials. A wide set of computational techniques and software, which falls under the category of computer-aided drug design (CADD), is routinely used during the first step of drug repurposing to pinpoint potential drug candidates. CADD includes a plethora of ligand-based and structure-based approaches, involving target structural validation, binding energy evaluation in both static and dynamic models, and pharmacokinetics prediction.
already passed safety assessments. Understandably, antiviral agents were among the first agents to be tested against COVID-19. This approach led to the approval of Remdesivir as the first treatment for hospitalized patients,[66–68] but not without controversies, due to uncertain outcomes of many clinical trials.[67,69,70]

Long MD simulations have become a state-of-art computational tool in CADD[23] as they represent the best tool to validate in silico results of molecular docking and virtual screening campaigns. Here, we report insights from MD simulations applied to the discovery of potential drugs able to interfere with the binding between RBD and ACE2. Only molecules tested both in vitro and in silico are reported.

One of the first computational works on SARS-CoV-2 proposed denopamine (Table 1A), bometolol, and Rotigaptide as possible inhibitors of S protein-ACE2 binding.[71] The authors tested denopamine in vitro, observing a diminishing of RBD binding at denopamine concentrations > 100 μM.[71] An in silico study highlighted simprevir and lumacaftor as putative RBD binders.[72] Lumacaftor (Table 1B) was subsequently proved to weakly bind to S protein with an IC50 of 84 ± 4 μM, although showing a good inhibition profile in Vero-E6 assays.[73] Simprevir (Table 1C) reduces the cellular viral load, synergizing with Remdesivir, but this effect was attributed to a direct action on the main protease and the RNA-dependent RNA polymerase (RdRp).[74] Post-docking MD simulations identified GSK1838705A, BMS195614, KT185, RS504393 and KT203 (Table 1D–H), five compounds from the Sigma–Aldrich library of pharmacologically active compounds (LOPAC), as potential binders of the S protein.[75] A retrospective MD investigation on arbidol (Table 1I), a therapeutic agent approved in China and Russia for influenza, showed an inhibitor effect on the original SARS spike protein[76] and arbidol intercalated between different spike protein subunits, and so affecting the trimerization of the S protein.[77] Docking and MD simulations performed by ourselves[78] and others[79] proposed Nilotinib (Table 1J) as a potential binder of the RBD or disruptor of the RBD–ACE2 complex. The anti-SARS-CoV potential of nilotinib was first reported in 2016 in the early stages of infection by inhibiting viral fusion at the endosomal level.[80] A couple of years later further results pointed out an action of nilotinib and other Abl kinase inhibitors, on the virus-cell membrane fusion.[81] In a recent study, the EC50 of imatinib was quantified as 1.44 and 3.06 μM in Vero-E6 cells and human respiratory cells, respectively.[82] Therefore, no experimental evidence for imatinib binding to RBD has been reported. The same goes for nafamostat, which we suggested as a putative RBD binder,[78] but it is proposed to act as a TMPRSS2 inhibitor in the low nanomolar range.[83,84]

**Box 2**

From a technical perspective, the amount of MD sampling to confirm molecular docking predictions has been generally limited to the time scale of a few tens of nanoseconds and this has probably produced numerous in silico false positives, undermining the credibility of computation studies. Simulations over tens or few hundreds of nanoseconds showing a docking complex as stable should not be faithfully trusted. For example, a molecule with a residence time of few microseconds (way longer than usual MD post-docking simulations) and an optimistic binding koff of ≈107 M⁻¹ s⁻¹ would have a kinetic affinity of about 10⁻² M and therefore would not be a binder despite the indication provided by MD.

**PERSPECTIVES FOR TARGETING THE SPIKE PROTEIN**

Although the worldwide effort to discover approved drugs to repurpose against the SARS-CoV-2 S protein, to date no MD-based study has delivered working hypotheses resulting in clinical trials. Open access COVID-19 drug repurposing databases[90,91] are a precious source of information but do not consider potential therapeutic agents proposed in silico; thus, there is a coordination gap between theoretical and experimental scientific communities.[92]

The discrepancy between the time scale of the real world and the simulated models (Box 2) can be partially overcome with end-state methods such as the MM-PBSA or MM-GBSA,[93] which can quantify the binding free energy using short MD simulations. However, the accuracy of these methods is system dependent and usually best suited for comparisons between congenic ligands[94] rather than very different chemotypes, as is usually required by repurposing strategies. Enhanced MD sampling techniques such as metadynamics[95] speed up the time required to dissociate docking complexes and allow estimation of the stability of the bound ligand, and can therefore assist in recognizing docking false positives.

We screened in silico more than 2000 approved small molecules.[78] After the docking and post-docking MD simulations of the best-ranked compounds docked in situ to the RBD, we performed a further step consisting of simulating the encounter of the RBD and ACE2 in the presence of the best compounds. Despite the stability displayed during the cefsulodin/RBD simulations, ACE2 easily displaced the proposed ligand in half of the supervised MD (SuMD)[96,97] replicas. Increasing the complexity of the modeled system highlighted the limit of common computational protocols for correctly selecting small molecules able to hinder the recognition between the S protein and ACE2. Therefore, dynamic approaches that consider the formation of the ternary systems between the S protein, ACE2, and the potential binding inhibitor should be routinely considered. Besides this, structure-based drug repurposing strategies should take into account the fully glycosylated S protein and the discovery of allosteric sites on the RBD to overcome the targeting obstacles. The extreme flexibility of the glycans on the surface of the S protein and the effective steric hindrance they offer affect the ability of antibodies or potential therapeutic molecules to bind to a sufficiently exposed epitope.[98] To combat this, Haji-Ghassemi et al. suggested searching for drugs to target this shield[99] this is a different approach from the traditional protein-oriented one.
| A | Denopamine: cardiotonic drug acting as an agonist at the β1 adrenergic receptor; used in the treatment of angina[^85] |
| B | Lumacaftor: used for the treatment of cystic fibrosis in patients that present the F508del in the CFTR (cystic fibrosis transmembrane conductance regulator) protein[^15]; IC<sub>50</sub> of 84 ± 4 μM toward the S protein |
| C | Simeprevir: inhibitor of the hepatitis C virus (HCV) NS3/NS4A protease[^71,87]; IC<sub>50</sub> of 9.6 ± 2.3 μM toward the M<sup>pro</sup> and an IC<sub>50</sub> value of 5.5 ± 0.2 μM toward the RdRp (RNA-dependent RNA polymerase)[^74] |
| D | GSK1838705A: inhibitor of the insulin-like growth factor-1 receptor (IGF-IR), insulin receptor and anaplastic lymphoma kinase (ALK)[^88] |
| E | BMS195614: antagonist of the retinoic acid receptor (RAR) |
| F | KT185: inhibitor of α/β-hydrolase domain-containing 6 (ABHD6) in the brain and liver of mice |
| G | RS504393: antagonist of the CC2 chemokine receptor |
| H | KT203: inhibitor of ABHD6 activity in the liver of mice |

(Continues)
TABLE 1 (Continued)

|   |   |
|---|---|
|   |   |
|   |   |

**Arbidol:** used as a treatment for influenza and other respiratory infections in Russia and China[77]

**Nilotinib:** a BCR-ABL tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia (CML)[88]

MD, molecular dynamics; RBD, receptor-binding domain.

**MOLECULAR DYNAMICS INSIGHTS ON NEW SARS-COV-2 VARIANTS**

Since the beginning of the pandemic, the evolutionary impact of SARS-CoV-2 was kept under observation by the scientific community to evaluate the possible effects of mutations on transmissibility, severity, and viral evasion of the immune mechanism.[100-103] Among the SARS-CoV-2 variants, the major preoccupations regarded those strains that carried important mutations and deletions, especially on the RBD (categorized as variants of concern [VOC]).[100] Such VOC have important RBD mutations: B.1.1.7 (Alpha) carries E484K, N501Y, D614G, P681H; B.1.351 (Beta) carries K417N, E484K, N501Y, D614G, A701V; P1 (Gamma) carries K417T, E484K, N501Y, D614G, H655Y; B.1.617.2 (Delta) carries L452R, T478K, D614G, P681R.[102] Concerns among the scientific community have risen due to their potential to elude the immune system and overcome vaccine protection[104-106] despite showing an overall similarity between variants, which diverged only in terms of flexibility.[107]

More recently, a new B.1.1.529 (Omicron) VOC[108-110] carrying N440K, G446S, S477N, T478K, E484A, Q493K, N501Y, and Y505H mutations, and its lineages became predominant over the Delta variant, possibly due to a more rapid entry or different mechanism,[111-113] an enhanced ability to evade the immune system,[103,114,115] and its increased affinity for ACE2[103] although showing a milder pathogenic impact.[119] New VOCs are expected to pose a new threat should they become widespread[120,121] and further studies should follow to evaluate the potential risk of new mutations.

MD-based computational efforts evaluated the effect of omicron’s mutations on ACE2 binding strength,[118,122,123] suggesting that YG339D, N440K, S477N, T478K, Q493K, N501Y increase the binding affinity, as also reported by Socher et al.[124] S371L, S373R, S375F, K417N, G446S, E484A, G496S, Q498R, Y505H, on the other hand, decreased the binding affinity for ACE2. In agreement with a compensatory effect that moderates the binding strength of the enhancing mutations,[125] however, the reinforced network of hydrogen bonds, involving T500-D355, G502-K353, N487-Y83, as well as R493-D38, and A475-S19, paired with the electrostatic matching between R493-D38 and the loop shift caused by E484A and T478K mutation as suggested by Zhao et al.[126] suggesting an overall increase in the binding energy. These shifts seem to increase the complementarity between ACE2 and Omicron’s RBD and could be the reason for the increased binding affinity, as also highlighted by Nie et al.[127]

The advent of the new VOC highlighted the necessity to follow multiple paths, for a broad-spectrum therapeutic approach, which should not only consider RBD as the target of main interest but should also consider more conserved viral proteins among the variants. MD studies were carried out to investigate non-structural proteins (NSP) as potential druggable targets.[128,129] Vivek et al. suggested the NSP13 helicase ATP-binding sites as a druggable target, while Vardhan et al. included the NSP14 and NSP15 exonuclease and endonuclease, respectively. Both groups used phytochemical small molecules as target binders, which, however, still require experimental data to confirm their efficacy.

Alternatively, PF-07321332 a promising oral antiviral candidate against the main protease (MPro) catalytic dyad on residues His41-Cys145 was investigated using MD simulation by Macchiagodena et al., using preliminary data structures available.[130] According to Macchiagodena’s work, the formation of the thiolate-imidazolium, paired with the exposition of the nitrile warhead in the proximity of the Cys145 would allow for the electrophilic attack on the MPro, for effective enzyme inhibition.

However, MD is not the most adequate method to represent bond formation or breaking, but the insights provided by contact frequency and interatomic distances could support the description of the experimental data, once the PF-07321332-MPro complex structure will become publicly available.

Other attempts against MPro were done[130-133] but require further experimental data to validate the hypothesis. The RNA polymerase,[134] as well as the nucleocapsid[135] and envelope protein[136] were proposed as a druggable target, but these studies will require further confirmation by experimental data to verify whether NSPs could be considered viable targets.
CONCLUSION

As a state-of-the-art computational technique, MD has been broadly employed to interrogate the structure and function of the S protein at the atomic level to understand how its inherent flexibility modulates the binding to ACE2 receptors and, therefore, SARS-CoV-2 virulency. MD suggested unexpected flexibility of the stalk region S2, the role of glycans on the S protein surface, and the contribution of single residues on the RBD to the interactions with ACE2. MD contributed important dynamic and structural elements such as the minimum anagulation required for molecular recognition between ACE2 and RBD, the effects of mutations on the binding capacity of the S protein, and the structural and protective role of glycans. Through MD, it was possible to understand how the spontaneous motions that open the RBD from the “down” to “up” conformation, revealing numerous cryptic pockets, which are possible targets of new drugs. The “down” to “up” transition that the RBD undergoes before ACE2 recognition was another important phenomenon that MD delivered structural insights on.

From a future perspective, we believe there is scope for an increasingly important contribution of MD in the study of Ab and their rational development as therapeutic agents. Also, MD contributed to rationalizing in vitro data on potential S protein binding antagonists, but with limited utility in drug repurposing. Approaches to address COVID-19 start to fade away from drug repurposing and the S protein to more classic rational strategies to target functional viral proteins, as demonstrated by the main protease (Mpro) inhibitor nirmatrelvir, the first oral anti-COVID-19 drug approved by the FDA. In this scenario, it is plausible that MD will regain a central role in aiding the development of future new classes of therapeutics against SARS-CoV-2.

ACKNOWLEDGEMENTS

Ludovico Pipitò and Roxana-Maria Rujan are grateful for the receipt of a Coventry University Studentship.

CONFLICT OF INTEREST

The authors do not have any conflicts of interest to declare.

DATA AVAILABILITY STATEMENT

The data described in this review was obtained from the cited articles.

ORCID

Ludovico Pipitò  https://orcid.org/0000-0002-1824-7541
Roxana-Maria Rujan  https://orcid.org/0000-0002-4335-3338
Christopher A. Reynolds  https://orcid.org/0000-0001-9267-5141
Giuseppe Deganutti  https://orcid.org/0000-0001-8780-2986

REFERENCES

1. Chan, J. F. W., Yuan, S., Kok, K. H., To, K. K. W., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C. C. Y., Poon, R. W. S., Tsui, H. W., Lo, S. K. F., Chan, K. H., Poon, V. K. M., Chan, W. M., Ip, J. D., Cai, J. P., Cheng, V. C., ... Yuen, K. Y. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet, 395(10223), 514–523.
2. Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., Hu, Y., Tao, Z.-W., Tian, J. H., Pei, Y. Y., Yuan, M.-L., Zhang, Y.-L., Dai, F.-H., Liu, Y., Wang, Q.-M., Zheng, J. J., Xu, L., Holmes, E. C., & Zhang, Y. Z. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265–269.
3. Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Wang, Z., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R.-D., Liu, M. Q., Chen, Y., Shen, X.-R., Wang, X., ... Shi, Z.-L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273.
4. Siddell, S. G. (1995). The coronaviridae: An introduction. In S. G. Siddell (Ed.), The Coronaviridae (pp. 1–10). Springer US.
5. Ragab, D., Salah Eldin, H., Taeimah, M., Khattab, R., & Salem, R. (2020). The COVID-19 cytokine storm: what we know so far. Frontiers in Immunology, 11, 1446.
6. Bosch, B. J., Van Der Zee, R., De Haan, C. A. M., & Rottier, P. J. M. (2003). The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex. Journal of Virology, 77(16), 8801–8811.
7. Xia, X. (2021). Domains and functions of spike protein in Sars-CoV-2 in the context of vaccine design. Viruses, 13(1), 109.
8. Fan, X., Cao, D., Kong, L., & Zhang, X. (2020). Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein. Nature Communications, 11(1), 3618.
9. Al Adem, K., Shanti, A., Stefanini, C., & Lee, S. (2020). Inhibition of SARS-CoV-2 entry into host cells using small molecules. Pharmaceuticals (Basel), 13(12), 447.
10. Tikellis, C., & Thomas, M. C. (2012). Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. International Journal of Peptide, 2012, 256294.
11. Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L., Abiona, O., Graham, B. S., & Mcclennan, J. S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367(6483), 1260–1263.
12. Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., & Wang, X. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, 581(7807), 215–220.
13. Benton, D. J., Wrobel, A. G., Xu, P., Roustan, C., Martin, S. R., Rosenthal, P. B., Skehel, J. J., & Gamblin, S. J. (2020). Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature, 588(7837), 327–330.
14. Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020). Cell entry mechanisms of SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 117(21), 11727–11734.
15. Berman, H. M. (2000). The protein data bank. Nucleic Acids Research, 28(1), 235–242.
16. Ke, Z., Oton, J., Qu, K., Cortese, M., Zila, V., Mckean, L., Nakane, T., Zivanov, J., Neufeld, C. J., Cerikan, B., Lu, J. M., Peukes, J., Xiong, X., Kräusslich, H. G., Scheres, S. H. W., Bartenschlager, R., & Briggs, J. A. G. (2020). Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature, 588(7838), 498–502.
17. Henderson, R., Edwards, R. J., Mansouri, K., Janowska, K., Stalls, V., Gobeil, S. M. C., Kopp, M., Li, D., Parks, R., Hsu, A. L., Borgia, M. J., Haynes, B. F., & Acharya, P. (2020). Controlling the SARS-CoV-2 spike glycoprotein conformation. Nature Structural & Molecular Biology, 27(10), 925–933.
18. Turoňová, B., Sikora, M., Schurmann, C., Hagen, W. J. H., Welsch, S., Blanc, F. E. C., Von Bülow, S., Gecht, M., Bagola, K., Hörner, C., Locker, J., & Beck, M. (2020). In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. Science, 370(6513), 203–208.
33. Verkhivker, G. (2022). Conformational flexibility and local frustration in the functional states of the SARS-CoV-2 spike B.1.1.7 and antibody binding of the fully glycosylated full-length SARS-CoV-2 spike protein. Nature Structural & Molecular Biology, 29, 1586–1592.

34. Takeda, M. (2022). Proteolytic activation of SARS-CoV-2 spike protein. Microbiology and Immunology, 66(1), 15–23.

35. Schaefer, S. L., Jung, H., & Hummer, G. (2021). Binding of SARS-CoV-2 fusion peptide to host endosome and plasma membrane. Journal of Physical Chemistry B, 125(28), 7732–7741.

36. Remington, J. M., Mckay, K. T., Ferrell, J. B., Schneebeli, S. T., & Li, J. (2021). Enhanced sampling protocol to elucidate fusion peptide opening of SARS-CoV-2 spike protein. Biophysical Journal, 120(14), 2848–2858.

37. Pavlova, A., Zhang, Z., Acharya, A., Lynch, D. L., Pang, Y. T., Mou, Z., Parks, J. M., Chipot, C., & Gumbart, J. C. (2021). Machine learning reveals the critical interactions for SARS-CoV-2 spike protein binding to ACE2. Journal of Physical Chemistry Letters, 12(23), 5494–5502.

38. Giron, C. C., Laaksonen, A., & Barroso Da Silva, F. L. S. (2021). Up state of the SARS-CoV-2 spike homotrimer favors an increased virulence for new variants. Frontiers in Medical Technology, 3, 694347.

39. Ali, A., & Vijayan, R. (2020). Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms. Scientific Reports, 10(1), 14214.

40. Barros, E. P., Casalino, L., Gaieb, Z., Dommer, A. C., Wang, Y., Fallon, L., Ragouette, L., Belfon, K., Simmerling, C., & Amaro, R. E. (2021). The flexibility of ACE2 in the context of SARS-CoV-2 infection. Biophysical Journal, 120(6), 1072–1084.

41. Mehdipour, A. R., & Hummer, G. (2021). Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike. Proceedings of the National Academy of Sciences of the United States of America, 118(19), e2100425118.

42. Williams, J. K., Wang, B., Sam, A., Hoop, C. L., Case, D. A., & Baum, J. (2021). Molecular dynamics analysis of a flexible loop at the binding interface of the SARS-CoV-2 spike protein receptor-binding domain. Proteins, 90(5), 1044–1053.

43. Peng, C., Zhu, Z., Shi, Y., Wang, X., Mu, K., Yang, Y., Zhang, X., Xu, Z., & Zhu, W. (2020). Computational Insights into the Conformational Accessibility and Binding Strength of SARS-CoV-2 Spike Protein to Human Angiotensin-Converting Enzyme 2. Journal of Physical Chemistry Letters, 11(24), 10482–10488.

44. Zuckermann, D. M., & Chong, L. T. (2017). Weighted ensemble simulation: Review of methodology, applications, and software. Annual Review of Biophysics, 46, 43–57.

45. Sztain, T., Ahn, S. H., Bogetti, A. T., Casalino, L., Goldsmith, J. A., Seitz, E., Mccool, R. S., Kearns, F. L., Acosta-Reyes, F., Maji, S., Mashayekhi, G., McCammon, J. A., Ournazad, A., Frank, J., Mclellan, J. S., Chong, L. T., & Amaro, R. E. (2021). A glycan gate controls opening of the SARS-CoV-2 spike protein. Nature Chemistry, 13(10), 963–968.

46. Harbison, A. M., Fogarty, C. A., Phung, T. K., Satheesan, A., Schulz, B. L., & Fadda, E. (2022). Fine-tuning the spike: Role of the nature and accessibility and Binding Strength of SARS-CoV-2 Spike Protein for new variants. ACS Central Science, 6(10), 1722–1734.

47. Casalino, L., Dommer, A., Gaieb, Z., Barros, E. P., Sztaín, T., Ahn, S. H., Trifan, A., Brand, A. T., Clyde, A., Ma, H., Lee, H., Turilli, M., Khalid, S., Chong, L. T., Simmerling, C., Hardy, D. J., Maia, J. D. C., Phillips, J. C., ... Amaro, R. E. (2021). AI-driven multiscale simulations illuminate mechanisms of SARS-CoV-2 spike dynamics. The International Journal of High Performance Computing Applications, 35(5), 432–451. https://doi.org/10.1108/10343039146591877

48. Yao, H., Song, Y., Chen, Y., Wu, N., Xu, J., Sun, C., Zhang, J., Weng, T., Zhang, Z., Wu, Z., Cheng, L., Shi, D., Lu, X., Lei, J., Crispin, M., Shi, Y., Li, L., & Li, S. (2020). Molecular architecture of the SARS-CoV-2 virus. Cell, 183(3), 730–738.e113.
52. Dokainish, H. M., Re, S., Mori, T., Kobayashi, C., Jung, J., & Sugita, Y. (2022). The inherent flexibility of receptor-binding domains in SARS-CoV-2 spike protein. eLife, 11, e75720.

53. Kamiya, M., & Sugita, Y. (2018). Flexible selection of the solute region in replica exchange with solute tempering: Application to protein-folding simulations. Journal of Physical Chemistry, 149(7), 072304.

54. Zimmerman, M. I., Porter, J. R., Ward, M. D., Singh, S., Vithani, N., Meller, A., Mallimadugula, U. L., Kuhn, C. E., Borowsky, J. H., Wiewiora, R. P., Hurley, M. F. D., Harbison, A. M., Fogarty, C. A., Coffland, J. E., Fadda, E., Voelz, V. A., Chodera, J. D., & Bowman, G. R. (2021). SARS-CoV-2 simulations go exascale to predict dramatic spike opening and cryptic pockets across the proteome. Nature Chemistry, 13(7), 651–659.

55. Sikora, M., von Bülow, S., Blanc, F. E. C., Gecht, M., Covino, R., & Zimmerman, M. I., Porter, J. R., Ward, M. D., Singh, S., Vithani, N., Meller, A., Mallimadugula, U. L., Kuhn, C. E., Borowsky, J. H., Wiewiora, R. P., Hurley, M. F. D., Harbison, A. M., Fogarty, C. A., Coffland, J. E., Fadda, E., Voelz, V. A., Chodera, J. D., & Bowman, G. R. (2021). SARS-CoV-2 simulations go exascale to predict dramatic spike opening and cryptic pockets across the proteome. Nature Chemistry, 13(7), 651–659.

56. Jokinen, E., Niemcewicz, M., Podogrocki, M., Saluk-Bijak, J., & Bijak, M. (2021). Detection of binding sites on SARS-CoV-2 spike protein-receptor-binding domain by molecular dynamics simulations in mixed solvents. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 18(4), 1281–1289.

57. Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., Mcnamee, C., Norris, A., Sansseau, P., Cavalla, D., & Pirmohamed, M. (2019). Drug repurposing: Progress, challenges and recommendations. Nature Reviews Drug Discovery, 18(1), 41–58.

58. Janik, E., Niemcewicz, M., Podogrocki, M., Saluk-Bijak, J., & Bijak, M. (2021). Existing drugs considered as promising in COVID-19 therapy. International Journal of Molecular Sciences, 22(11), 5434.

59. Fantini, J., Chahinian, H., & Yahi, N. (2020). Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. International Journal of Antimicrobial Agents, 56(2), 10620.

60. Gu, H., Krishnan, P., Ng, D. Y. M., Chang, L. D. J., Liu, G. Y. Z., Cheng, S. T., Gopinath, K., Kurkinen, S. T., & Pentikainen, O. (2021). COVID-19 vaccines: The status and perspectives in delivery points of view. Advanced Drug Delivery Reviews, 170, 1–25.

61. Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Jokinen, E. M., Gopinath, K., Kurkinen, S. T., & Pentikainen, O. (2021). COVID-19 vaccines: The status and perspectives in delivery points of view. Advanced Drug Delivery Reviews, 170, 1–25.

62. Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zimng, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez De Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., ... Lane, H. C. (2020). Remdesivir for the treatment of Covid-19 – final report. New England Journal of Medicine, 383(19), 1813–1826.

63. Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., ... Wang, C. (2020). Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 395(10236), 1569–1578.

64. Gottlieb, R. L., Vaca, C. E., Paredes, R., Mera, J., Webb, B. J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B. U., Brown, M., Hidalgo, A., Sachdeva, Y., Mittal, S., Osiyemi, O., Skarbinski, J., Juneja, K., Hyland, R. L., Osinski, A., Chen, S., ... Hill, J. A. (2022). Early remdesivir to prevent progression to severe Covid-19 in outpatients. New England Journal of Medicine, 386(4), 305–315.

65. Cohen, J. (2020). ‘A very, very bad look’ for remdesivir. Science, 370, 642–643.

66. Sreekanth Reddy, O., & Lai, W. F. (2021). Tackling COVID-19 using remdesivir and favipiravir as therapeutic options. ChemBioChem, 22(6), 939–948.

67. Durdagi, S., Orhan, M. D., Aksoydan, B., Calis, S., Dogan, B., Sahin, K., Shahraki, A., Iyison, N. B., & Avsar, T. (2021). Screening of clinically approved and investigation drugs as potential inhibitors of SARS-CoV-2: A combined in silico and in vitro study. Molecular Information, 41, e2100062.

68. Trezza, A., Iovinelli, D., Prischi, F., Santucci, A., & Spiga, O. (2020). An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors. Scientific Reports, 10, 13866.

69. Day, C. J., Bailly, B., Guillion, P., Dirr, L., Jen, F. E.-C., Spillings, B. L., Mak, J., Von Itzstein, M., Haselhorst, T., & Jennings, M. P. (2021). Multidisciplinary approaches identify compounds that bind to human ACE2 or SARS-CoV-2 spike protein as candidates to block SARS-CoV-2-AE2 receptor interactions. mBio, 12(2), e03681–20.

70. Lo, H. S., Hui, K. P. Y., Lai, H. M., He, X., Khan, K. S., Kaur, S., Huang, J., Li, Z., Chan, A. K. N., Cheung, H. H. Y., Ng, K.-C., Ho, J. C. W., Chen, Y. W., Ma, B., Cheung, P. M. H., Shin, D., Wang, K., Lee, M. H., Selisko, B., ... Ng, W. L. (2021). Simprevir potently suppresses SARS-CoV-2 replication and synergizes with remdesivir. ACS Central Science, 7(5), 792–802.

71. Choudhary, S., Malik, Y. S., & Tomar, S. (2020). Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach. Frontiers in Immunology, 11, 1664.

72. Zhang, J., Zhou, L., Yang, Y., Peng, W., Wang, W., & Chen, X. (2020). Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. The Lancet Respiratory Medicine, 8(3), e11–e12.

73. Vankadari, N. (2020). Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. International Journal of Antimicrobial Agents, 56(2), 105998.

74. Deganutti, G., Prischi, F., & Reynolds, C. A. (2021). Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein. Journal of Computer-Aided Molecular Design, 35(2), 195–207.

75. Razizadeh, M., Nikfar, M., & Liu, Y. (2021). Small molecule therapeutics to destabilize the ACE2-RBD complex: A molecular dynamics study. Biophysical Journal, 120(14), 2793–2804.

76. Coleman, C. M., Sisk, J. M., Mingo, R. M., Nelson, E. A., White, J. M., & Frieman, M. B. (2016). Abelson kinase inhibitors are potent inhibitors...
of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus. Journal of Virology, 90(19), 8924–8933.

81. Sisk, J. M., Friedman, M. B., & Machamer, C. E. (2018). Coronavirus S protein-induced fusion is blocked prior to hemifusion by Ab1 kinase inhibitors. Journal of General Virology, 99(5), 619–630.

82. Cagno, V., Magliocco, G., Tapparel, C., & Daeli, Y. (2021). The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro. Basic & Clinical Pharmacology & Toxicology, 128(4), 621–624.

83. Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlnmann, S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2), 271–280.e8.

84. Zhu, H., Du, W., Song, M., Liu, Q., Herrmann, A., & Huang, Q. (2021). Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TPRMSS2. Computational and Structural Biotechnology Journal, 19, 467–476.

85. Nakajima, D., Negoro, N., Nakaboh, A., Nakakoji, T., Hoshiga, M., Nariyama, J., Ishihara, T., & Hanafusa, T. (2006). Effectiveness of low dose denosumab, a beta1-adrenoceptor agonist, in a patient with vasospastic angina refractory to intensive medical treatment. International Journal of Cardiology, 108(2), 281–283.

86. Saint-Criq, V., & Gray, M. A. (2017). Role of CFTR in epithelial physiology. Molecular Cancer Therapeutics, 10(12), 2811–2820.

87. Raboisson, P., de Kock, H., Rosenquist, A., Nilsson, M., Salvador, M., Albitar, M., Griffin, J. D., Hoelzer, D., Al-D�ewiri, L., Atkins, C., Dumble, M., Yang, J., Anderson, K., Kruger, R. G., Gontarek, D. D., (2022). Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature, 553–556.

88. Al-Tawfiq, J. A., Koritala, T., Alhumaid, S., Barry, M., Alshukairi, A. N., Temsah, M. H., Al Mutair, A., Rabaan, A., Tirupathi, R., & Gautret, P. (2021). Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants. Cellular and Molecular Life Sciences, 78(24), 7967–7989.

89. Iketani, S., Liu, L., Guo, Y., Liu, L., Chan, J. F.-W., Huang, Y., Wang, M., Luo, Y., Yu, J., Chu, H., Chik, K.-H., Yuen, T. T.-T., Yin, M. T., Sobieszczky, M. E., Huang, Y., Yuen, K. Y., Wang, H. H., Sheng, Z., & Ho, D. D. (2022). Antibody evasion properties of SARS-CoV-2 Omicron variants. Nature, 583–596.

90. Mistry, P., Barmania, F., Mellet, J., Peta, K., Strydom, A., Viljoen, I. M., Sobieszczky, M. E., Huang, Y., Yuen, K. Y., Wang, H. H., Sheng, Z., & Ho, D. D. (2022). Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature, 553–556.

91. Brimacombe, K. R., Zhao, T., Eastman, R. T., Hu, X., Wang, K., Backus, M., Balijnyniam, B., Chen, C. Z., Chen, L., Eicher, T., Ferrer, M., Fu, Y., Gorskv, K., Guo, H., Hanson, Q. M., Itkin, Z., Kales, S. C., Klumpp-Thomas, C., Lee, E. M., ... Shen, M. (2020). An OpenData portal to share COVID-19 drug repurposing data in real time. BioRxiv, https://doi.org/10.1101/2020.06.04.135046

92. Galindez, G., Matschinke, J., Rose, T. D., Sadegh, S., Salgado-Albarrán, M., Späth, J., Baumbach, J., & Pauling, J. K. (2021). Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. Nature Computational Science, 1(1), 33–41.

93. Wang, E., Sun, H., Wang, J., Wang, Z., Liu, H., Zhang, J. Z. H., & Hou, T. (2019). End-point binding free energy calculation with MM/PBSA and MM/GBSA: Strategies and applications in drug design. Chemical Reviews, 119(16), 9478–9508.

94. Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion Drug Discovery, 10(5), 449–461.

95. Barducci, A., Bonomi, M., & Pannella, M. (2010). Linking well-tempered metadynamics simulations with experiments. Biophysical Journal, 98(9), L44–L46.

96. Sabbadin, D., & Moro, S. (2014). Supervised molecular dynamics (SuMD) as a helpful tool to depict GPCR-ligand recognition pathway in a nanosecond time scale. Journal of Chemical Information and Modeling, 54(2), 372–376.

97. Cuzzolin, A., Sturlese, M., Deganutti, G., Salmaso, V., Sabbadin, D., Ciancetta, A., & Moro, S. (2016). Deciphering the complexity of ligand-protein recognition pathways using supervised molecular dynamics (SuMD) simulations. Journal of Chemical Information and Modeling, 56(4), 687–705.

98. Homans, S. W., Dwek, R. A., Boyd, J., Mahmoudian, M., Richards, W. G., & Rademacher, T. W. (1986). Conformational transitions in N-linked oligosaccharides. Biochemistry, 25(20), 6342–6350.

99. Haji-Ghasemi, O., Blackler, R. J., Martin Young, N., & Evans, S. V. (2015). Antibody recognition of carbohydrate epitopes†. Glycobiology, 25(9), 920–952.

100. Choi, J. Y., & Smith, D. M. (2021). SARS-CoV-2 variants of concern. Vossei Medical Journal, 62(11), 961–968.

101. Thakur, V., & Ratho, R. K. (2021). OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear. Journal of Medical Virology, https://doi.org/10.1002/jmv.27541

102. Gupta, D., Sharma, P., Singh, M., Kumar, M., Ethayathulla, A. S., & Kaur, D. D. (2022). Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature, 553–556.

103. Al-Tawfiq, J. A., Koritala, T., Alhumaid, S., Barry, M., Alshukairi, A. N., Temsah, M. H., Al Mutair, A., Rabaan, A., Tirupathi, R., & Gautret, P. (2022). Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness. Infection, 583–596.

104. Mistry, P., Barmania, F., Mellet, J., Peta, K., Strydom, A., Viljoen, I. M., James, W., Gordon, S., & Pepper, M. S. (2021). SARS-CoV-2 variants, vaccines, and host immunity. Front Immunology, 12, 809244.

105. Mccarty, K. R., Rennick, L. J., Nambulli, S., Robinson-McCarty, L. R., Bain, W. G., Haidar, G., & Duprex, W. P. (2021). Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science, 371(6534), 1139–1142.

106. Mandal, N., Padhi, A. K., & Rath, S. L. (2022). Molecular insights into the differential dynamics of SARS-CoV-2 variants of concern. Journal of Molecular Graphics and Modelling, 114, 108194.

107. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. [Internet]. (2022, May 14). https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern

108. Kannan, S., Shaik Syed Ali, P., & Sheeza, A. (2021). Omicron (B.1.1.529) – variant of concern – molecular profile and epidemiology: A mini review. European Review for Medical and Pharmacological Sciences, 25(24), 8019–8022.

109. Gao, S. J., Guo, H., & Luo, G. (2021). Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert! Journal of Medical Virology, 94(4), 1255–1256.

110. Peacock, T. P., Brown, J. C., Zhou, J., Thakur, N., Newman, J., Kugathasan, R., Sukhova, K., Kafourou, M., Bailey, D., & Barclay, W. S.
(2022). The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. BioRxiv. https://doi.org/10.1101/2021.12.31.474653

112. Callaway, E. (2022). Why does the Omicron sub-variant spread faster than the original? Nature. 602(7902), 556–557.

113. Arora, P., Zhang, L., Rocha, C., Sidarovich, A., Schulz, S., Kempf, A., Graichen, L., Moldenhauer, A. S., Cosmann, A., Dopfer-Jablonska, A., Behrens, G. M. N., JÄSck, H. M., & Hoffmann, M. (2022). SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Cell Host & Microbe. https://doi.org/10.1016/j.chom.2022.04.017

114. Tukeprakhon, A., Nutilai, R., Dijokai-te-Guralicu, A., Zhou, D., Ginn, H. M., Selvaraj, M., Liu, C., Centner, A. J., Supasa, P., Duveyestyn, H. M., E., Das, R., Skelly, D., Ritter, T. G., Amini, A., Bibi, S., Adele, S., Johnson, S. A., Constantiniades, B., Webster, H., … Temperton, N. (2022). Antobody Escape of SARS-CoV-2 Omicron BA.4 and BA.5 from Vaccine and BA.1 Serum. Cell. 185(14), 2422–2433.

115. Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamashita, D., Gerber, P. P., Fatihi, S., Rathore, S., Zepeda, S. K., Papa, G., Kemp, S. A., Ikeda, T., Toyoda, M., Tan, T. S., Kuramochi, J., Mitsunaga, S., Ueno, T., … Shirakawa, K. (2022). Altered TMPRSS2 Usage by SARS-CoV-2 Omicron Impacts Infectivity and Fusogenicity. Nature. 603(7902), 706–714.

116. Kumar, R., Murugan, N. A., & Srivastava, V. (2021). Improved binding affinity of the Omicron’s spike protein with hACE2 receptor is the key factor behind its increased virulence. BioRxiv. https://doi.org/10.1101/2021.12.28.474338

117. Yin, W., Xu, Y., Xu, P., Cao, X., Wu, C., Gu, C., He, X., Wang, X., Huang, S., Yuan, Q., Wu, K., Hu, W., Huang, Z., Liu, J., Wang, Z., Jia, F., Xia, K., Liu, P., Wang, X., … Song, B. (2022). Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody. Science. 375(6584), 1048–1053.

118. Lupalka, C. S., Ye, Y., Chen, H., Su, X. D., & Liu, H. (2022). Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor. Biochemical and Biophysical Research Communications. 590, 34–41.

119. Shuai, H., Chan, J. F.-W., Hu, B., Chai, Y., Yuen, T. T.-T., Yin, F., Huang, X., Yoon, C., Hu, J. C., Liu, H., Shi, J., Liu, Y., Zhu, T., Zhang, J., Hou, Y., Wang, Y., Lu, L., Cai, J. P., Zhang, A. J., … Chu, H. (2022). Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature. 693, 699–699.

120. Yamasoba, D., Kosugi, Y., Kimura, I., Fujita, S., Uriu, K., Ito, J., Sato, K., The Genotype to Phenotype Japan (G2P-Japan) Consortium. (2022). Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies. BioRxiv. https://doi.org/10.1101/2022.05.03.490409

121. Khan, K., Karim, F., Gang, Y., Bernstein, M., Jule, Z., Reedy, K., Ceier, S., Luslig, G., Amoako, D., Wolter, N., Samsunder, N., Sivo, A., San, J. E., Giandhari, J., Tegally, H., Pillay, S., Naidoo, Y., Muzibuko, M., Miya, Y., … Sigal, A. (2022). Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity. medRxiv. https://doi.org/10.1101/2022.04.29.22274477

122. Wu, L., Zhou, L., Mo, M., Liu, T., Wu, C., Gong, C., Lu, K., Gong, L., Zhu, W., & Xu, Z. (2022). SARS-CoV-2 Omicron RBD Shows Weaker Binding Affinity than the Currently Dominant Delta Variant to Human ACE2. Signal Transduction and Targeted Therapy. 7(1), 8.

123. Jawaid, M. Z., Baidya, A., Mahboubi-Ardakani, R., Davis, R. L., & Cox, D. L. (2021). Simulation of the omicron variant of SARS-CoV-2 shows broad antibody escape, weakened ACE2 binding, and modest increase in furin binding. BioRxiv. https://doi.org/10.1101/2021.12.14.472704

124. Socher, E., Heger, L., Paulsen, F., Zunke, F., & Arnold, P. (2022). Molecular dynamics simulations of the delta and omicron SARS-CoV-2 spike – ACE2 complexes reveal distinct changes between both variants. Computational and Structural Biotechnology. 20, 1168–1176.

125. Wu, L., Zhou, L., Mo, M., Liu, T., Wu, C., Gong, C., Lu, K., Gong, L., Zhu, W., & Xu, Z. (2022). SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2. Signal Transduction and Targeted Therapy. 7(1), 8.

126. Zhao, X., Xiong, D., Luo, S., & Duan, L. (2022). Origin of the tight binding mode to ACE2 triggered by multi-point mutations in the omicron variant: A dynamic insight. Physical Chemistry Chemical Physics. 24(15), 8724–8737.

127. Nie, C., Sahoo, A. K., Netz, R. R., Herrmann, A., Ballauf, M., & Haag, R. (2022). Charge matters: Mutations in omicron variant favor binding to cells. ChemBioChem. 23(6), 202100681.

128. Vivek-Ananth, R. P., Krishnaswamy, S., & Samal, A. (2022). Potential photochemical inhibitors of SARS-CoV-2 helicase Nsp13: A molecular docking and dynamic simulation study. Molecular Diversity, 26(1), 429–442.

129. Vardhan, S., & Sahoo, S. K. (2022). Exploring the therapeutic nature of limonoids and triterpenoids against SARS-CoV-2 by targeting nsp13, nsp14, and nsp15 through molecular docking and dynamic simulations. Journal of Traditional and Complementary Medicine, 12(1), 44–54.

130. Macchiagodena, M., Pagliai, M., & Procacci, P. (2022). Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease. Journal of Molecular Graphics and Modelling. 110, 108042.

131. Shree, P., Mishra, P., Selvaraj, C., Singh, S. K., Chauve, R., Garg, N., & Tripathi, Y. B. (2022). Targeting COVID-19 (SARS-CoV-2) main protease through active photochemicals of ayurvedic medicinal plants – Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) – a molecular docking study. Journal of Biomolecular Structure and Dynamics, 40(1), 190–203.

132. El Khattabi, K., Aanaaz, I., Alaqarbeh, M., Ajana, M. A., Lakhlifi, T., & Bouachrine, M. (2022). Molecular docking, molecular dynamics simulation, and ADMET analysis of levamisole derivatives against the SARS-CoV-2 main protease (MPro). Bioimpacts. 12(2), 107–113.

133. Raman, A. P. S., Singh, M. B., Vishvakarma, V. K., Jain, P., Kumar, A., Sachdeva, S., Kumari, K., & Singh, P. (2022). An investigation for the interaction of gamma oryzanol with the Mpro of SARS-CoV-2 to combat COVID-19: DFT, molecular docking, ADME and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 1–11.

134. Eflick, A. A., Mahar, H. A., Ibrahim, I. M., Ibrahim, M. N., & Elshemey, W. M. (2022). Molecular dynamics simulations and MM-GBSA reveal novel guanosine derivatives against SARS-CoV-2 RNA dependent RNA polymerase. RSC Advances. 12(5), 2741–2750.

135. Ahamad, S., Gupta, D., & Kumar, V. (2022). Targeting SARS-CoV-2 nucleoside oligomerization: Insights from molecular docking and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 40(6), 2430–2443.

136. Kuzmin, A., Orekhov, P., Astashkin, R., Gordelii, V., & Gushchin, I. (2022). Structure and dynamics of the SARS-CoV-2 envelope protein monomer. Proteins, 90(5), 1102–1114.